| 张 勇,邱军杰,安亚东,黄 洁,陈彩云.氯沙坦联合环磷腺苷葡胺对肺心病患者心肺及免疫功能的影响[J].现代生物医学进展英文版,2018,(5):931-934. |
| 氯沙坦联合环磷腺苷葡胺对肺心病患者心肺及免疫功能的影响 |
| Effect of Losartan Combined with Cyclic Adenosine Monophosphate on the Heart, Lung and Immune Functions of Patients with Pulmonary Heart Disease |
| Received:April 28, 2017 Revised:May 24, 2017 |
| DOI：10.13241/j.cnki.pmb.2018.05.029 |
| 中文关键词: 氯沙坦 环磷腺苷葡胺 肺心病 心肺功能 疗效 |
| 英文关键词: Losartan Cyclic adenosine monophosphate Pulmonary heart disease Heart and lung function Effect |
| 基金项目:陕西省自然科学基金项目(2013JM4041) |
|
| Hits: 556 |
| Download times: 353 |
| 中文摘要: |
| 摘要 目的：探讨氯沙坦联合环磷腺苷葡胺对肺心病患者心肺功能和免疫功能的影响。方法：选择2010年9月至2015年9月我院接诊的94例肺心病患者并按随机数表法分为观察组和对照组，每组各47例。对照组给予常规肺心病治疗，观察组在对照组的基础上给予氯沙坦联合环磷腺苷葡胺进行治疗。比较两组治疗前后CO、LVEF、SV、FEV1及FEV1/FV、IgG、IgA、补体C3、血清白细胞介素-2(interleukin-2，IL-2)、可溶性白细胞介素2受体(soluble interleukin-2 receptor，sIL-2R)、8-异前列腺素(8-ISO prostaglandin，8-iso-PG)水平的变化以及治疗后的临床疗效。结果：治疗后，观察组CO、LVEF、SV、FEV1及FEV1/FVC水平均显著高于对照组[(5.21±0.27) vs (4.15±0.46)，(63.42±6.17) vs (52.37±5.76)，(74.68±9.24) vs (64.56±11.73)，(1.75±0.27) vs (1.32±0.31)，(75.68±10.62) vs (65.49±10.05)](P<0.05)，血清补体C3高于对照组[(1.34±0.12) g/L vs(1.16±0.10) g/L] (P<0.05)；血清sIL-2R、8-iso-PG水平显著低于对照组[(371.46±161.06) U/ml vs (435.75±152.43) U/ml,(23.58±11.72) ng/L vs (31.08±11.39) ng/L] (均P<0.05)；观察组总有效率高于对照组[(95.74)% vs(78.72)%] (P<0.05)。结论：氯沙坦联合环磷腺苷葡胺可有效提高肺心病患者心、肺及免疫功能。 |
| 英文摘要: |
| ABSTRACT Objective: To study the curative efficacy of losartan combined with cyclic adenosine monophosphate in the treatment of pulmonary heart disease and the serum levels of IL-2, sIL-2R and 8-iso-PG. Methods: 94 patients with pulmonary heart disease who were treated from September 2010 to September 2015 were selected and randomly divided into the observation group and the control group with 47 cases in each group. The control group was treated with conventional treatment of pulmonary heart disease, while the ob- servation group was treated with losartan and cyclic adenosine monophosphate on the basis of control group. Then the cardiac function, pulmonary function, immune function, serum levels of IL-2, sIL-2R and 8-iso-PG and curative effect in the two groups were observed and compared before and after the treatment. Results: After treatment, the cardiac function improved in both groups (P<0.05); The levels of CO, LVEF, SV, FEV1 and FEV1 / FVC in the observation group were higher than those of the control group [(5.21±0.27) vs (4.15±0.46)，(63.42±6.17) vs (52.37±5.76)，(74.68±9.24) vs (64.56±11.73)，(1.75±0.27) vs (1.32±0.31)，(75.68±10.62) vs (65.49±10.05)] (P<0.05); The complement C3 level of observation group was higher than that of the control group[(1.34±0.12) g/L vs(1.16±0.10) g/L] (P<0.05); The levels of sIL-2R and 8-iso-PG of observation group were lower than those of the control group [(371.46±161.06) U/ml vs(435.75±152.43) U/ml, (23.58±11.72) ng/L vs(31.08±11.39) ng/L] (P<0.05). The total effective rate of observation group was higher than that of the control group [95.74% vs78.72%] (P<0.05). Conclusion: Losartan combined with adenosine cyclophos- phamide could improve the heart, lung and immune function, enhance the level of complement C3, and improve the symptoms of is- chemia and hypoxia. |
|
View Full Text
View/Add Comment Download reader |
| Close |
